JAHA:既往动脉粥样硬化血栓形成疾病患者房颤和冠状动脉疾病的抗血栓治疗

2021-10-18 MedSci原创 MedSci原创

与联合治疗相比,利伐沙班单药治疗可显著减少房颤、冠状动脉疾病和既往动脉粥样硬化血栓形成疾病患者的不良事件。

在房颤和稳定型冠状动脉疾病患者中,既往有动脉粥样硬化血栓形成病史的患者未来发生缺血事件的风险很高。

近日,血管疾病领域权威杂志JAHA上发表了一篇研究文章,该研究旨在调查利伐沙班单药治疗心房颤动、冠状动脉疾病和动脉粥样硬化血栓形成病史患者的疗效和安全性。

该研究是对稳定型冠状动脉疾病患者使用利伐沙班治疗心房颤动和缺血事件(AFIRE)试验进行的事后亚组分析。非瓣膜性房颤和冠状动脉疾病患者被招募并随机接受利伐沙班单药治疗或利伐沙班加抗血小板药物联合治疗。参与者被分为2个亚组,包括动脉粥样硬化血栓形成组(有心肌梗塞、卒中和/或外周动脉疾病病史的患者;n=1052,47.5%)和非动脉粥样硬化血栓形成组(n=1163,52.5%)。该研究的疗效终点包括心血管事件或全因死亡,而安全终点为大出血。净不良事件包括全因死亡、心肌梗塞、卒中或大出血。

在动脉粥样硬化血栓形成组中,与联合治疗相比,利伐沙班单药治疗与较低的净不良事件风险显著相关(风险比[HR]为0.50;95%CI为0.34-0.74;P<0.001),两者疗效(HR为0.68;95%CI为0.47-0.99;P=0.044)和安全(HR为0.37;95%CI为0.19-0.71;P=0.003)终点均显著降低。相比之下,非动脉粥样硬化组的治疗结果之间没有差异。

由此可见,与联合治疗相比,利伐沙班单药治疗可显著减少房颤、冠状动脉疾病和既往动脉粥样硬化血栓形成疾病患者的不良事件。

原始出处:

Yasushi Matsuzawa.et al.Antithrombotic Therapy for Atrial Fibrillation and Coronary Artery Disease in Patients With Prior Atherothrombotic Disease: A Post Hoc Analysis of the AFIRE Trial.JAHA.2021.https://www.ahajournals.org/doi/full/10.1161/JAHA.121.020907

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1799179, encodeId=5a081e9917921, content=<a href='/topic/show?id=38e0e0670ff' target=_blank style='color:#2F92EE;'>#疾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70670, encryptionId=38e0e0670ff, topicName=疾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Sun Nov 28 10:26:30 CST 2021, time=2021-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944719, encodeId=3d9a1944e19f3, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Fri Jul 29 01:26:30 CST 2022, time=2022-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063720, encodeId=c0aa1063e200e, content=认真学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=368487940, createdName=zjw, createdTime=Mon Oct 25 11:25:20 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252961, encodeId=841412529618e, content=<a href='/topic/show?id=463230886b8' target=_blank style='color:#2F92EE;'>#冠状动脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30886, encryptionId=463230886b8, topicName=冠状动脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Oct 20 13:26:30 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268649, encodeId=2ffd12686498d, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Wed Oct 20 13:26:30 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385532, encodeId=f93113855321a, content=<a href='/topic/show?id=1ea455e6064' target=_blank style='color:#2F92EE;'>#抗血栓治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55760, encryptionId=1ea455e6064, topicName=抗血栓治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef33504, createdName=wsusan1966, createdTime=Wed Oct 20 13:26:30 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574142, encodeId=30a815e41423d, content=<a href='/topic/show?id=ee4955e5730' target=_blank style='color:#2F92EE;'>#抗血栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55757, encryptionId=ee4955e5730, topicName=抗血栓)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a26516008049, createdName=gwc388, createdTime=Wed Oct 20 13:26:30 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061688, encodeId=57891061688c5, content=重症和危重症病人达到78,678例;全球新, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Tue Oct 19 07:11:17 CST 2021, time=2021-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061671, encodeId=7dc310616e13f, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/e9408422a23545ef9738dd674abfc4ff/c719925083844b82986bc39d43051172.jpg, createdBy=8eb14795142, createdName=与狼共舞, createdTime=Tue Oct 19 06:13:37 CST 2021, time=2021-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061634, encodeId=52ce1061634ad, content=有一定参考价值, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6af1554625, createdName=8242649, createdTime=Mon Oct 18 23:04:42 CST 2021, time=2021-10-18, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1799179, encodeId=5a081e9917921, content=<a href='/topic/show?id=38e0e0670ff' target=_blank style='color:#2F92EE;'>#疾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70670, encryptionId=38e0e0670ff, topicName=疾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Sun Nov 28 10:26:30 CST 2021, time=2021-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944719, encodeId=3d9a1944e19f3, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Fri Jul 29 01:26:30 CST 2022, time=2022-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063720, encodeId=c0aa1063e200e, content=认真学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=368487940, createdName=zjw, createdTime=Mon Oct 25 11:25:20 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252961, encodeId=841412529618e, content=<a href='/topic/show?id=463230886b8' target=_blank style='color:#2F92EE;'>#冠状动脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30886, encryptionId=463230886b8, topicName=冠状动脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Oct 20 13:26:30 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268649, encodeId=2ffd12686498d, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Wed Oct 20 13:26:30 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385532, encodeId=f93113855321a, content=<a href='/topic/show?id=1ea455e6064' target=_blank style='color:#2F92EE;'>#抗血栓治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55760, encryptionId=1ea455e6064, topicName=抗血栓治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef33504, createdName=wsusan1966, createdTime=Wed Oct 20 13:26:30 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574142, encodeId=30a815e41423d, content=<a href='/topic/show?id=ee4955e5730' target=_blank style='color:#2F92EE;'>#抗血栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55757, encryptionId=ee4955e5730, topicName=抗血栓)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a26516008049, createdName=gwc388, createdTime=Wed Oct 20 13:26:30 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061688, encodeId=57891061688c5, content=重症和危重症病人达到78,678例;全球新, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Tue Oct 19 07:11:17 CST 2021, time=2021-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061671, encodeId=7dc310616e13f, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/e9408422a23545ef9738dd674abfc4ff/c719925083844b82986bc39d43051172.jpg, createdBy=8eb14795142, createdName=与狼共舞, createdTime=Tue Oct 19 06:13:37 CST 2021, time=2021-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061634, encodeId=52ce1061634ad, content=有一定参考价值, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6af1554625, createdName=8242649, createdTime=Mon Oct 18 23:04:42 CST 2021, time=2021-10-18, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1799179, encodeId=5a081e9917921, content=<a href='/topic/show?id=38e0e0670ff' target=_blank style='color:#2F92EE;'>#疾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70670, encryptionId=38e0e0670ff, topicName=疾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Sun Nov 28 10:26:30 CST 2021, time=2021-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944719, encodeId=3d9a1944e19f3, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Fri Jul 29 01:26:30 CST 2022, time=2022-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063720, encodeId=c0aa1063e200e, content=认真学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=368487940, createdName=zjw, createdTime=Mon Oct 25 11:25:20 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252961, encodeId=841412529618e, content=<a href='/topic/show?id=463230886b8' target=_blank style='color:#2F92EE;'>#冠状动脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30886, encryptionId=463230886b8, topicName=冠状动脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Oct 20 13:26:30 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268649, encodeId=2ffd12686498d, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Wed Oct 20 13:26:30 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385532, encodeId=f93113855321a, content=<a href='/topic/show?id=1ea455e6064' target=_blank style='color:#2F92EE;'>#抗血栓治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55760, encryptionId=1ea455e6064, topicName=抗血栓治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef33504, createdName=wsusan1966, createdTime=Wed Oct 20 13:26:30 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574142, encodeId=30a815e41423d, content=<a href='/topic/show?id=ee4955e5730' target=_blank style='color:#2F92EE;'>#抗血栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55757, encryptionId=ee4955e5730, topicName=抗血栓)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a26516008049, createdName=gwc388, createdTime=Wed Oct 20 13:26:30 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061688, encodeId=57891061688c5, content=重症和危重症病人达到78,678例;全球新, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Tue Oct 19 07:11:17 CST 2021, time=2021-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061671, encodeId=7dc310616e13f, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/e9408422a23545ef9738dd674abfc4ff/c719925083844b82986bc39d43051172.jpg, createdBy=8eb14795142, createdName=与狼共舞, createdTime=Tue Oct 19 06:13:37 CST 2021, time=2021-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061634, encodeId=52ce1061634ad, content=有一定参考价值, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6af1554625, createdName=8242649, createdTime=Mon Oct 18 23:04:42 CST 2021, time=2021-10-18, status=1, ipAttribution=)]
    2021-10-25 zjw

    认真学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1799179, encodeId=5a081e9917921, content=<a href='/topic/show?id=38e0e0670ff' target=_blank style='color:#2F92EE;'>#疾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70670, encryptionId=38e0e0670ff, topicName=疾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Sun Nov 28 10:26:30 CST 2021, time=2021-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944719, encodeId=3d9a1944e19f3, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Fri Jul 29 01:26:30 CST 2022, time=2022-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063720, encodeId=c0aa1063e200e, content=认真学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=368487940, createdName=zjw, createdTime=Mon Oct 25 11:25:20 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252961, encodeId=841412529618e, content=<a href='/topic/show?id=463230886b8' target=_blank style='color:#2F92EE;'>#冠状动脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30886, encryptionId=463230886b8, topicName=冠状动脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Oct 20 13:26:30 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268649, encodeId=2ffd12686498d, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Wed Oct 20 13:26:30 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385532, encodeId=f93113855321a, content=<a href='/topic/show?id=1ea455e6064' target=_blank style='color:#2F92EE;'>#抗血栓治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55760, encryptionId=1ea455e6064, topicName=抗血栓治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef33504, createdName=wsusan1966, createdTime=Wed Oct 20 13:26:30 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574142, encodeId=30a815e41423d, content=<a href='/topic/show?id=ee4955e5730' target=_blank style='color:#2F92EE;'>#抗血栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55757, encryptionId=ee4955e5730, topicName=抗血栓)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a26516008049, createdName=gwc388, createdTime=Wed Oct 20 13:26:30 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061688, encodeId=57891061688c5, content=重症和危重症病人达到78,678例;全球新, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Tue Oct 19 07:11:17 CST 2021, time=2021-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061671, encodeId=7dc310616e13f, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/e9408422a23545ef9738dd674abfc4ff/c719925083844b82986bc39d43051172.jpg, createdBy=8eb14795142, createdName=与狼共舞, createdTime=Tue Oct 19 06:13:37 CST 2021, time=2021-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061634, encodeId=52ce1061634ad, content=有一定参考价值, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6af1554625, createdName=8242649, createdTime=Mon Oct 18 23:04:42 CST 2021, time=2021-10-18, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1799179, encodeId=5a081e9917921, content=<a href='/topic/show?id=38e0e0670ff' target=_blank style='color:#2F92EE;'>#疾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70670, encryptionId=38e0e0670ff, topicName=疾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Sun Nov 28 10:26:30 CST 2021, time=2021-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944719, encodeId=3d9a1944e19f3, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Fri Jul 29 01:26:30 CST 2022, time=2022-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063720, encodeId=c0aa1063e200e, content=认真学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=368487940, createdName=zjw, createdTime=Mon Oct 25 11:25:20 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252961, encodeId=841412529618e, content=<a href='/topic/show?id=463230886b8' target=_blank style='color:#2F92EE;'>#冠状动脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30886, encryptionId=463230886b8, topicName=冠状动脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Oct 20 13:26:30 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268649, encodeId=2ffd12686498d, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Wed Oct 20 13:26:30 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385532, encodeId=f93113855321a, content=<a href='/topic/show?id=1ea455e6064' target=_blank style='color:#2F92EE;'>#抗血栓治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55760, encryptionId=1ea455e6064, topicName=抗血栓治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef33504, createdName=wsusan1966, createdTime=Wed Oct 20 13:26:30 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574142, encodeId=30a815e41423d, content=<a href='/topic/show?id=ee4955e5730' target=_blank style='color:#2F92EE;'>#抗血栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55757, encryptionId=ee4955e5730, topicName=抗血栓)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a26516008049, createdName=gwc388, createdTime=Wed Oct 20 13:26:30 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061688, encodeId=57891061688c5, content=重症和危重症病人达到78,678例;全球新, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Tue Oct 19 07:11:17 CST 2021, time=2021-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061671, encodeId=7dc310616e13f, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/e9408422a23545ef9738dd674abfc4ff/c719925083844b82986bc39d43051172.jpg, createdBy=8eb14795142, createdName=与狼共舞, createdTime=Tue Oct 19 06:13:37 CST 2021, time=2021-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061634, encodeId=52ce1061634ad, content=有一定参考价值, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6af1554625, createdName=8242649, createdTime=Mon Oct 18 23:04:42 CST 2021, time=2021-10-18, status=1, ipAttribution=)]
    2021-10-20 zhaohui6731
  6. [GetPortalCommentsPageByObjectIdResponse(id=1799179, encodeId=5a081e9917921, content=<a href='/topic/show?id=38e0e0670ff' target=_blank style='color:#2F92EE;'>#疾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70670, encryptionId=38e0e0670ff, topicName=疾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Sun Nov 28 10:26:30 CST 2021, time=2021-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944719, encodeId=3d9a1944e19f3, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Fri Jul 29 01:26:30 CST 2022, time=2022-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063720, encodeId=c0aa1063e200e, content=认真学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=368487940, createdName=zjw, createdTime=Mon Oct 25 11:25:20 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252961, encodeId=841412529618e, content=<a href='/topic/show?id=463230886b8' target=_blank style='color:#2F92EE;'>#冠状动脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30886, encryptionId=463230886b8, topicName=冠状动脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Oct 20 13:26:30 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268649, encodeId=2ffd12686498d, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Wed Oct 20 13:26:30 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385532, encodeId=f93113855321a, content=<a href='/topic/show?id=1ea455e6064' target=_blank style='color:#2F92EE;'>#抗血栓治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55760, encryptionId=1ea455e6064, topicName=抗血栓治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef33504, createdName=wsusan1966, createdTime=Wed Oct 20 13:26:30 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574142, encodeId=30a815e41423d, content=<a href='/topic/show?id=ee4955e5730' target=_blank style='color:#2F92EE;'>#抗血栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55757, encryptionId=ee4955e5730, topicName=抗血栓)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a26516008049, createdName=gwc388, createdTime=Wed Oct 20 13:26:30 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061688, encodeId=57891061688c5, content=重症和危重症病人达到78,678例;全球新, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Tue Oct 19 07:11:17 CST 2021, time=2021-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061671, encodeId=7dc310616e13f, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/e9408422a23545ef9738dd674abfc4ff/c719925083844b82986bc39d43051172.jpg, createdBy=8eb14795142, createdName=与狼共舞, createdTime=Tue Oct 19 06:13:37 CST 2021, time=2021-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061634, encodeId=52ce1061634ad, content=有一定参考价值, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6af1554625, createdName=8242649, createdTime=Mon Oct 18 23:04:42 CST 2021, time=2021-10-18, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1799179, encodeId=5a081e9917921, content=<a href='/topic/show?id=38e0e0670ff' target=_blank style='color:#2F92EE;'>#疾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70670, encryptionId=38e0e0670ff, topicName=疾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Sun Nov 28 10:26:30 CST 2021, time=2021-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944719, encodeId=3d9a1944e19f3, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Fri Jul 29 01:26:30 CST 2022, time=2022-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063720, encodeId=c0aa1063e200e, content=认真学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=368487940, createdName=zjw, createdTime=Mon Oct 25 11:25:20 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252961, encodeId=841412529618e, content=<a href='/topic/show?id=463230886b8' target=_blank style='color:#2F92EE;'>#冠状动脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30886, encryptionId=463230886b8, topicName=冠状动脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Oct 20 13:26:30 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268649, encodeId=2ffd12686498d, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Wed Oct 20 13:26:30 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385532, encodeId=f93113855321a, content=<a href='/topic/show?id=1ea455e6064' target=_blank style='color:#2F92EE;'>#抗血栓治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55760, encryptionId=1ea455e6064, topicName=抗血栓治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef33504, createdName=wsusan1966, createdTime=Wed Oct 20 13:26:30 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574142, encodeId=30a815e41423d, content=<a href='/topic/show?id=ee4955e5730' target=_blank style='color:#2F92EE;'>#抗血栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55757, encryptionId=ee4955e5730, topicName=抗血栓)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a26516008049, createdName=gwc388, createdTime=Wed Oct 20 13:26:30 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061688, encodeId=57891061688c5, content=重症和危重症病人达到78,678例;全球新, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Tue Oct 19 07:11:17 CST 2021, time=2021-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061671, encodeId=7dc310616e13f, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/e9408422a23545ef9738dd674abfc4ff/c719925083844b82986bc39d43051172.jpg, createdBy=8eb14795142, createdName=与狼共舞, createdTime=Tue Oct 19 06:13:37 CST 2021, time=2021-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061634, encodeId=52ce1061634ad, content=有一定参考价值, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6af1554625, createdName=8242649, createdTime=Mon Oct 18 23:04:42 CST 2021, time=2021-10-18, status=1, ipAttribution=)]
    2021-10-20 gwc388
  8. [GetPortalCommentsPageByObjectIdResponse(id=1799179, encodeId=5a081e9917921, content=<a href='/topic/show?id=38e0e0670ff' target=_blank style='color:#2F92EE;'>#疾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70670, encryptionId=38e0e0670ff, topicName=疾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Sun Nov 28 10:26:30 CST 2021, time=2021-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944719, encodeId=3d9a1944e19f3, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Fri Jul 29 01:26:30 CST 2022, time=2022-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063720, encodeId=c0aa1063e200e, content=认真学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=368487940, createdName=zjw, createdTime=Mon Oct 25 11:25:20 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252961, encodeId=841412529618e, content=<a href='/topic/show?id=463230886b8' target=_blank style='color:#2F92EE;'>#冠状动脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30886, encryptionId=463230886b8, topicName=冠状动脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Oct 20 13:26:30 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268649, encodeId=2ffd12686498d, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Wed Oct 20 13:26:30 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385532, encodeId=f93113855321a, content=<a href='/topic/show?id=1ea455e6064' target=_blank style='color:#2F92EE;'>#抗血栓治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55760, encryptionId=1ea455e6064, topicName=抗血栓治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef33504, createdName=wsusan1966, createdTime=Wed Oct 20 13:26:30 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574142, encodeId=30a815e41423d, content=<a href='/topic/show?id=ee4955e5730' target=_blank style='color:#2F92EE;'>#抗血栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55757, encryptionId=ee4955e5730, topicName=抗血栓)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a26516008049, createdName=gwc388, createdTime=Wed Oct 20 13:26:30 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061688, encodeId=57891061688c5, content=重症和危重症病人达到78,678例;全球新, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Tue Oct 19 07:11:17 CST 2021, time=2021-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061671, encodeId=7dc310616e13f, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/e9408422a23545ef9738dd674abfc4ff/c719925083844b82986bc39d43051172.jpg, createdBy=8eb14795142, createdName=与狼共舞, createdTime=Tue Oct 19 06:13:37 CST 2021, time=2021-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061634, encodeId=52ce1061634ad, content=有一定参考价值, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6af1554625, createdName=8242649, createdTime=Mon Oct 18 23:04:42 CST 2021, time=2021-10-18, status=1, ipAttribution=)]
    2021-10-19 查查佳佳

    重症和危重症病人达到78,678例;全球新

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1799179, encodeId=5a081e9917921, content=<a href='/topic/show?id=38e0e0670ff' target=_blank style='color:#2F92EE;'>#疾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70670, encryptionId=38e0e0670ff, topicName=疾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Sun Nov 28 10:26:30 CST 2021, time=2021-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944719, encodeId=3d9a1944e19f3, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Fri Jul 29 01:26:30 CST 2022, time=2022-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063720, encodeId=c0aa1063e200e, content=认真学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=368487940, createdName=zjw, createdTime=Mon Oct 25 11:25:20 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252961, encodeId=841412529618e, content=<a href='/topic/show?id=463230886b8' target=_blank style='color:#2F92EE;'>#冠状动脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30886, encryptionId=463230886b8, topicName=冠状动脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Oct 20 13:26:30 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268649, encodeId=2ffd12686498d, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Wed Oct 20 13:26:30 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385532, encodeId=f93113855321a, content=<a href='/topic/show?id=1ea455e6064' target=_blank style='color:#2F92EE;'>#抗血栓治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55760, encryptionId=1ea455e6064, topicName=抗血栓治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef33504, createdName=wsusan1966, createdTime=Wed Oct 20 13:26:30 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574142, encodeId=30a815e41423d, content=<a href='/topic/show?id=ee4955e5730' target=_blank style='color:#2F92EE;'>#抗血栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55757, encryptionId=ee4955e5730, topicName=抗血栓)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a26516008049, createdName=gwc388, createdTime=Wed Oct 20 13:26:30 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061688, encodeId=57891061688c5, content=重症和危重症病人达到78,678例;全球新, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Tue Oct 19 07:11:17 CST 2021, time=2021-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061671, encodeId=7dc310616e13f, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/e9408422a23545ef9738dd674abfc4ff/c719925083844b82986bc39d43051172.jpg, createdBy=8eb14795142, createdName=与狼共舞, createdTime=Tue Oct 19 06:13:37 CST 2021, time=2021-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061634, encodeId=52ce1061634ad, content=有一定参考价值, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6af1554625, createdName=8242649, createdTime=Mon Oct 18 23:04:42 CST 2021, time=2021-10-18, status=1, ipAttribution=)]
    2021-10-19 与狼共舞

    学习学习

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1799179, encodeId=5a081e9917921, content=<a href='/topic/show?id=38e0e0670ff' target=_blank style='color:#2F92EE;'>#疾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70670, encryptionId=38e0e0670ff, topicName=疾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Sun Nov 28 10:26:30 CST 2021, time=2021-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944719, encodeId=3d9a1944e19f3, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Fri Jul 29 01:26:30 CST 2022, time=2022-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063720, encodeId=c0aa1063e200e, content=认真学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=368487940, createdName=zjw, createdTime=Mon Oct 25 11:25:20 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252961, encodeId=841412529618e, content=<a href='/topic/show?id=463230886b8' target=_blank style='color:#2F92EE;'>#冠状动脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30886, encryptionId=463230886b8, topicName=冠状动脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Oct 20 13:26:30 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268649, encodeId=2ffd12686498d, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Wed Oct 20 13:26:30 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385532, encodeId=f93113855321a, content=<a href='/topic/show?id=1ea455e6064' target=_blank style='color:#2F92EE;'>#抗血栓治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55760, encryptionId=1ea455e6064, topicName=抗血栓治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef33504, createdName=wsusan1966, createdTime=Wed Oct 20 13:26:30 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574142, encodeId=30a815e41423d, content=<a href='/topic/show?id=ee4955e5730' target=_blank style='color:#2F92EE;'>#抗血栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55757, encryptionId=ee4955e5730, topicName=抗血栓)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a26516008049, createdName=gwc388, createdTime=Wed Oct 20 13:26:30 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061688, encodeId=57891061688c5, content=重症和危重症病人达到78,678例;全球新, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Tue Oct 19 07:11:17 CST 2021, time=2021-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061671, encodeId=7dc310616e13f, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/e9408422a23545ef9738dd674abfc4ff/c719925083844b82986bc39d43051172.jpg, createdBy=8eb14795142, createdName=与狼共舞, createdTime=Tue Oct 19 06:13:37 CST 2021, time=2021-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061634, encodeId=52ce1061634ad, content=有一定参考价值, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6af1554625, createdName=8242649, createdTime=Mon Oct 18 23:04:42 CST 2021, time=2021-10-18, status=1, ipAttribution=)]
    2021-10-18 8242649

    有一定参考价值

    0

相关资讯

Neurology:房颤、卒中和无症状脑血管疾病的关系

AF与广泛的脑血管病变有关。需要进一步研究以确定是否可以将脑血管MRI标志物添加到当前的治疗指南中,以进一步个性化AF患者的抗凝治疗,并进一步归纳AF与脑血管疾病以及痴呆之间关联的潜在发病机制。

Stroke:肥厚型心肌病患者根据房颤有无患缺血性卒中的情况

HCM患者AF患病率高,IS风险明显,HCM患者伴有AF与较差的结局独立相关。一个简单的法国HCM评分显示了HCM患者中IS的良好预测和临床有用性,具有良好的校准。

Neurology:卒中后心房颤动检测的生物标志物:系统评价和荟萃分析

研究确定了多模式生物标志物,它们可以帮助指导缺血性卒中/短暂性脑缺血发作(TIA)后心脏监测的患者选择。他们的预后效用应该以房颤检测和复发卒中作为结果进行前瞻性评估。

Circulation:早期心律控制治疗给心衰合并房颤的患者带来的临床益处

有心衰体征或症状的患者确诊合并房颤后 1 年内开始心律控制治疗可带来显著的临床益处

J INTERN MED:较高针对apoB100 p210的自身抗体水平与女性较低的房颤发生率相关

心房颤动(AF)与全身和心房组织炎症相关。这些结果支持自身体液免疫与房颤之间的关联。

JAMA子刊:早发房颤、心肌病及心律失常的罕见基因突变的流行率

心房颤动(AF)是最常见的心律失常疾病,影响着全球3000多万人。